Roche, Alexion ripe for showdown in a race to treat rare CNS disorder
Months after Alexion’s $ALXN flagship Soliris enthralled investors with impressive pivotal data for patients with neuromyelitis optica spectrum disorder (NMSOD), researchers at Roche’s Chugai …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
